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ABSTRACT OF THE DISSERTATION
THE EFFECT OF VITAMIN D3 SUPPLEMENTATION ON KIDNEY FUNCTION
AND CARDIOVASCULAR DISEASE MARKERS AMONG HISPANICS AND
AFRICAN AMERICANS WITH TYPE 2 DIABETES
by
Gustavo G. Zarini
Florida International University, 2017
Miami, Florida
Professor Fatma G. Huffman, Major Professor
Serum vitamin D deficiency/insufficiency, Chronic Kidney Disease (CKD) and
elevated blood pressure are important health concerns especially among
minorities with type 2 diabetes. The effect of vitamin D3 supplementation
(cholecalciferol) at 6,000 IU/day (d) vs. 4,000 IU/d on kidney function and
cardiovascular disease markers among Hispanics and African Americans with
type 2 diabetes and hypovitaminosis D (<30 ng/ml) was evaluated. Subjects
(n=63) were recruited from two clinics in Miami-Dade County, FL. Fasting venous
blood and fresh, single-voided first morning urine samples were collected from
each participant by a certified phlebotomist and analyzed by Solstas Lab
Partners, Davie, FL. Linear mixed models were used to compare the interaction
between time and intervention. Least Significant Difference (LSD) comparisons
were used to detect significant differences within and between 4,000 IU/d and
6,000 IU/d groups from baseline, 3 and 6 months. In the 4,000 IU/d and 6,000
IU/d groups, a significant increase in serum 25-hydroxy vitamin D [25(OH)D]
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levels were observed from baseline [(19.9±1.1 ng/mL) and (21.4±1.3 ng/mL)] to 3
months [(36.1±2.2 ng/mL, p<.001) and (43.0±2.7 ng/mL, p<0.001)]; and 6
months [(37.1±2.4 ng/mL, p<0.001) and (39.2±3.0 ng/mL, p<0.001)],
respectively. Significant increase in estimated Glomerular Filtration Rate (eGFR)
creatinine equation values were observed from baseline (81.2±3.0 mL/min) to 6
months (90.2±2.8 mL/min, p<0.001) in the 4,000 IU/d group. Significant decrease
in eGFR creatinine - cystatin C equation values were found from 3 months
(109.2±3.9 mL/min) to 6 months (100.9±3.7 mL/min, p=0.006) in the 4,000 IU/d
group. Systolic blood pressure levels significantly decreased from baseline
(144.1±4.0 mmHg) to 6 months (134.5±3.5 mmHg, p=0.020) only for the 6,000
IU/d group. Supplementation with vitamin D3 longer than 6 months may be
needed to determine sustained long term effects in kidney and cardiovascular
disease markers. Further research could provide more information for translation
of these findings into recommendations for individuals with CKD, hypertension
and type 2 diabetes. The efficacy of vitamin D3 supplementation as
complementary therapy for CKD and blood pressure in minority and other ethnic
groups needs further investigation in larger and longer duration randomized
controlled trials.
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CHAPTER I: INTRODUCTION
Kidney Disease
Kidney disease is the ninth leading cause of death in the U.S. (National
Center for Health Statistics, 2012) affecting 31 million (10%) of American adults
with the majority unaware of their conditions (CDC, 2011). Diabetes accounted
for 44% of the incidence of kidney failure in 2012 (American Kidney Fund, 2015).
Furthermore, complications from kidney disease are more prevalent in minorities:
End Stage Renal Disease (ESRD) was nearly 1.5 times more likely in Hispanics
as compared to non-Hispanic Whites (CDC, 2012).

The Kidney Disease Improving Global Outcomes (KDIGO) guidelines
(KDIGO, 2013) recommends using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation with serum creatinine for initial evaluation and
staging of kidney disease. The Modification of Diet in Renal Disease (MDRD)
equation may not be as reliable as the CKD-EPI equation for Glomerular
Filtration Rate (GFR) levels between 60 and 90 mL/min/1.73m2 (Levey et al.,
2009). Although the CKD-EPI equation (eGFR creatinine) adjust for age, gender
and race, serum creatinine is affected by variations in diet and lean muscle mass
(National Kidney Foundation, 2009). Cystatin C, a 13-kDa, single-chain amino
acid present in almost all nucleated cells (Abrahamson et al., 1990), has been
proposed as a confirmatory marker to add to the CKD-EPI equation, alone
(eGFR cystatin) or with serum creatinine (eGFR creatinine- cystatin C), when
eGFR creatinine is assumed inaccurate (KDIGO, 2013).
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Microalbuminuria is considered an early biomarker for loss of kidney function.
Microalbuminuria a sensitive marker recommended by the Kidney Disease
Outcomes Quality Initiative (KDOQI) Clinical Practice guidelines to be used to
assess and monitor kidney function in early stages of kidney disease (KDOQI,
2000). Reported in previous studies, microalbuminuria was associated with
cardiovascular disease and mortality in individuals with type 2 diabetes
(Mogensen, 1984; Valmadrid et al., 2000). The American Diabetes Association
recommends that individuals with type 2 diabetes be tested for microalbuminuria
at the diagnosis of diabetes and subsequently every year (American Diabetes
Association, 2009). Decrease in microalbuminuria values represents an
improvement in kidney function and possible reduction in cardiovascular disease
risk (KDOQI, 2000).

Kidney Disease and Vitamin D
The prevalence of chronic kidney disease (CKD) and hypovitaminosis D
disproportionately affects minorities and individuals with type 2 diabetes (Diaz et
al., 2009; Melamed et al., 2009; Zadshir et al., 2005). Data from the National
Health and Nutrition Examination Survey (NHANES) indicated that cases of
kidney disease were distributed disproportionally among Hispanics, with
Hispanics presenting the highest proportion of kidney disease (38.5%), followed
by non-Hispanic Blacks (36.2 %) and non-Hispanic Whites (27.8%) (Diaz et al.,
2009). Vitamin D status differ across ethnic groups. Non-Hispanic Blacks and
Hispanics have higher rates (80.4% and 59.0%) of serum 25-hydroxy vitamin D
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[25(OH)D] levels considered deficient as compared to Whites (39.5%, p<0.01)
(Diaz et al., 2009). Individuals with kidney disease had higher rates of serum
vitamin D deficiency (53.2%) as compared to those with normal kidney function
(47.0%) (Diaz et al., 2009). Individuals with kidney disease were shown to have
hypovitaminosis D even in the early stages of kidney disease (Lee et al., 2010).
Moreover, since their kidneys are deteriorated, the ability to activate adequate
amounts of vitamin D decline. Reduction in renal function over a 4-year period
was greater for individuals with insufficient serum 25(OH)D and diabetes in
Caucasian adults as compared to controls (de Boer et al., 2011). In a 5-year
follow-up study of a random sample of Caucasians (n=4,330), aged 30-60 years,
low 25(OH)D levels predicted higher protein excretion (Skaaby et al., 2013).
Serum 25(OH)D levels have been inversely associated with albuminuria in a U.S.
representative population and this association remained after controlling for
diabetes (de Boer et al., 2007).

Insufficient dietary and serum 25(OH)D levels could contribute to morbidity
and mortality (Heaney et al., 2005; Zimmermann & Gummert, 2010). In the
longitudinal study by Pilz et al. (2011), with a median follow-up time of 9.4 years,
the risk of mortality in 444 individuals with CKD (stages 3-5) was higher in those
with serum vitamin D deficiency as compared to those with normal vitamin D
status (hazard ratios: 4.38, 95% CI 2.13–9.00). The mechanism that could
explain the association between vitamin D status and mortality; however,
remains unknown. Sufficient levels of serum 25(OH)D are protective of the renal

3

and cardiovascular systems; conversely, hypovitaminosis D may accelerate
disease progression (Judd and Tangpricha, 2008; Li, 2012).

Kidney Disease and Vitamin D Supplementation
Supplementation that raises serum 25(OH)D levels has been recommended
to prevent health problems in adults (Heaney et al., 2005; Williams, et al., 2009).
Investigations of the effect of vitamin D3 supplementation on minorities with type
2 diabetes; however, have been limited. Most vitamin D supplementation trials in
patients with kidney disease have been conducted primarily in Caucasians
without diabetes. Vitamin D3 supplementation at high doses [>2000 IU/day (d)]
has promise for achieving vitamin D sufficiency for persons with CKD (Alvarez et
al., 2012). On the other hand, studies concerning vitamin D2 supplementation
and vitamin D status in kidney disease were less conclusive (Alvarez et al.,
2012). Vitamin D3 may provide a safer and more cost-effective strategy for the
treatment of early CKD than oral vitamin D2 or synthetic analogues. There are
some studies available on vitamin D3 supplementation in adults, in which kidney
function was measured (Kim et al., 2011; Rucker et al., 2009; Molina et al.,
2014). Vitamin D3 supplementation, provided according to the participant’s
vitamin D status, for 4 months showed a reduction of albuminuria, but no change
in GFR for ethnically diverse (43% Caucasian, 22% Black, and 45% Asian)
patients (n=63) with CKD stages 2-4 and hypovitaminosis D (Kim et al., 2011).
Supplementation of 1000 IU/daily of vitamin D3 among 128 Canadian adults with
later stages of kidney disease (stages 3-5) found no improvements in kidney
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function (GFR) compared with a control group; however, supplementation was of
short duration (3 months) and mean 25(OH)D levels were below vitamin D
sufficiency (30 ng/mL) by the end of the study (Rucker et al., 2009).
Supplementation of vitamin D3 at 666 IU/d for 6 months significantly lowered
albuminuria in a Caucasian older adult cohort (n= 101) with CKD stages 3-4, but
no significant improvements were found for estimated GFR (Molina et al., 2014).
Early supplementation with vitamin D3 might provide a more valuable treatment
and possibly delay adverse kidney disease outcomes.

Blood Pressure and Vitamin D
The Centers for Disease Control and Prevention (CDC) indicated that one in
3 individuals living in the U.S., an estimated 70 million adults, have high blood
pressure (CDC, 2015) which place them at higher risk to die from heart disease
(Nwankwo et al., 2013). The CDC recommended decreasing individual’s systolic
blood pressure by 12 to 13 mmHg because it could potentially reduce deaths
from cardiovascular disease by 25%. Still, high levels of blood pressure among
Hispanics and Blacks continue to be a challenge (CDC, 2013).

Serum vitamin D deficiency/insufficiency and elevated blood pressure are
important health concerns especially among minorities. Available evidence from
observational studies indicated that low 25(OH)D levels are related to elevated
blood pressure. A study by Schmitz et al. (2009) conducted in Hispanics and
African Americans (n=1334) found an inverse association between 25(OH)D
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levels and blood pressure, after adjusting for age, gender, ethnicity and seasons.
When BMI was included in the final model, blood pressure was no longer
associated with 25(OH)D levels. In this study, only a small proportion of subjects
had systolic blood pressure ≥ 140 mmHg (n=72; 5%) and diastolic blood
pressure ≥ 90 mmHg (n=93; 7%). Data from NHANES that included 12,644
individuals ≥ 20 years old showed that after adjusting for age, gender, ethnic
background, and physical activity, 25(OH)D levels were inversely linked with
blood pressure (Scragg et al., 2007). When the highest quintile of 25(OH)D (≥ 87
nmol/L) was compared to the lowest quintile (40.4 nmol/L), both mean systolic
blood pressure and diastolic blood pressure were 3.0 mmHg and 1.6 mmHg
lower in those in the highest quintile (Scragg et al., 2007). As in the study by
Schmitz et al. (2009), addition of BMI as an adjustment variable in the model
weakened the relationship between 25(OH)D and blood pressure levels. In the
study by Scragg et al. (2007), systolic blood pressure continued to be significant
despite adjustment. Likewise, Forman et al. (2007) found an inverse association
between 25(OH)D and incident risk of hypertension by exploring two cohorts
(men=613) from the Health Professionals’ Follow-up Study and Nurses’ Health
Study (women=1198) ages 40-75.

In contrast with the findings from observational studies, the relationship
between vitamin D3 supplementation and its effect on blood pressure is not as
clear. Clinical trials and meta-analyses have tried to elucidate the relationship
between vitamin D supplementation and blood pressure; however, findings from
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these studies are inconsistent. Results from some clinical trials and metaanalysis were not able to determine significant reductions in blood pressure
levels (Pittas et al., 2010; Witham et al., 2009; Jorde et al., 2010; Beveridge et
al., 2015; Larsen et al., 2012) while other investigations did find significant
improvements in blood pressure (Witham et al., 2010; Forman et al., 2013;
Pfeifer et al., 2001; Sugden et al., 2008). The mechanism of how vitamin D
affects blood pressure is poorly understood. Nonetheless, it has been postulated
that vitamin D could affect blood pressure regulation through the ReninAngiotensin-Aldosterone System (RAAS) (Li et al., 2004; Pilz et al., 2009).

Deficient/insufficient 25(OH)D levels could be corrected by vitamin D3
supplementation which may be of significance and have a potential impact on
health of minority groups with type 2 diabetes. Furthermore, improving blood
pressure levels using vitamin D3 may prevent future complications associated
with kidney and cardiovascular disease. The clinical importance of vitamin D3
supplementation as adjunct therapy is to prevent kidney and cardiovascular
disease complications.

Significance of the Study
Even though hypovitaminosis D, type 2 diabetes, kidney disease and
cardiovascular disease are major health problems affecting minorities, no study
so far has investigated the effect of two high doses of vitamin D3
supplementation (4,000 IU/d and 6,000 IU/d) exclusively among Hispanics and
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African Americans with type 2 diabetes and hypovitaminosis D. Supplementation
with vitamin D3 may have the potential of delaying and managing the progression
of CKD and cardiovascular disease. As an inexpensive and safe supplement,
vitamin D3 (cholecalciferol) could have significant benefit in reducing diabetes
complications and health disparities among Hispanics and African Americans
with type 2 diabetes.

Aims and Hypotheses
Aim 1: To evaluate the effect of vitamin D3 supplementation (cholecalciferol) at
6,000 IU/d vs. 4,000 IU/d on kidney function among Hispanics and African
Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml).
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
raising 25-hydroxy vitamin D [25(OH)D] levels from deficient/insufficient to
sufficient as compared to 4,000 IU/d over 6 months.
Hypothesis 2: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
increasing estimated glomerular filtration rate (eGFR) using CKD-EPI creatinine
equation (Chronic Kidney Disease Epidemiology Collaboration) when compared
to 4,000 IU/d over 6 months.
Hypothesis 3: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
increasing eGFR using CKD-EPI creatinine - cystatin C equation (Chronic Kidney
Disease Epidemiology Collaboration) when compared to 4,000 IU/d over 6
months.

8

Hypothesis 4: Vitamin D3 supplementation at 6,000 IU/d will be more effective
than the 4,000 IU/d over 6 months in lowering microalbuminuria measured by
first morning urine samples.

Aim 2: To evaluate the effect of vitamin D3 supplementation at 6,000 IU/d vs.
4,000 IU/d on markers of cardiovascular disease risk among Hispanics and
African Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml).
Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective
than the 4,000 IU/d over 6 months in lowering systolic and diastolic blood
pressure levels.
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Table 1: Summary of Aims, Hypotheses and Statistical Analyses
Dependent &
Aims

Hypotheses

Controlled

Statistical

Variables

Analysis

Independent
Variables

Aim 1: To evaluate the

Hypothesis 1: Vitamin D3

H1 –

Age gender,

All data analyses

effect of vitamin D3

supplementation at 6,000 IU/d

DV: DV:

BMI, known

for the study was

supplementation

will be more effective in raising

25(OH)D

years with

conducted on an

(cholecalciferol) at

25-hydroxy vitamin D

IV: vitamin D3

diabetes, A1c,

“intent to treat”

6,000 IU/d vs. 4,000

[25(OH)D] levels from

supplementation diabetes

IU/d on kidney function

deficient/insufficient to

medications,

among Hispanics and

sufficient as compared to

blood pressure variables was

African Americans with

4,000 IU/d over 6 months.

medications,

assessed.

type 2 diabetes and

vitamin D

Independent t-

hypovitaminosis D

intake, sun

test (parametric)

(<30 ng/ml).

exposure.

or Mann-Whitney

basis. Normal
distribution of all

U-test
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Hypothesis 2: Vitamin D3

H2 –

BMI, known

(nonparametric)

supplementation at 6,000 IU/d

DV: eGFR

years with

for continuous

will be more effective in

creatinine

diabetes, A1c,

variables and chi-

increasing eGFR using CKD-

IV: vitamin D3

diabetes

square test for

EPI creatinine equation

supplementation medications,

categorical

(Chronic Kidney Disease

blood pressure variables were

Epidemiology Collaboration)

medications,

used to compare

when compared to 4,000 IU/d

25(OH)D,

differences in

over 6 months.

vitamin D

baseline

intake, sun

characteristics of

exposure.

participants

Hypothesis 3: Vitamin D3

H3 –

BMI, known

across the two

supplementation at 6,000 IU/d

DV: eGFR

years with

intervention

will be more effective in

creatinine –

diabetes, A1c,

groups. For aims

increasing estimated

cystatin C

diabetes

1 and 2, mixed

glomerular filtration rate

IV: vitamin D3

medications,

models were
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(eGFR) using CKD-EPI

supplementation blood pressure performed using

creatinine - cystatin C equation

medications,

estimated

(Chronic Kidney Disease

25(OH)D,

glomerular

Epidemiology Collaboration)

vitamin D

filtration (eGFR)

when compared to 4,000 IU/d

intake, sun

rates,

over 6 months.

exposure.

microalbuminuria,

Hypothesis 4: Vitamin D3

H4 –

Age gender,

systolic and

supplementation at 6,000 IU/d

DV: MAU

BMI, known

diastolic blood

will be more effective than the

IV: vitamin D3

years with

pressure levels

4,000 IU/d over 6 months in

supplementation diabetes, A1c,

as the dependent

lowering microalbuminuria

diabetes

variable,

measured by first morning

medications,

respectively. The

urine samples.

blood pressure interaction

12

medications,

between time

25(OH)D,

and intervention

vitamin D

were included to

intake, sun

evaluate the

exposure.

dosage effect on

Age gender,

the change of the

Aim 2: To evaluate the

Hypothesis 1: Vitamin D3

H1 –

effect of vitamin D3

supplementation at 6,000 IU/d

DV: SBP & DBP BMI, known

dependent

supplementation at

will be more effective than the

IV: vitamin D3

variable over

6,000 IU vs. 4,000 IU/d

4,000 IU/d over 6 months in

supplementation diabetes, A1c,

on markers of

lowering systolic and diastolic

diabetes

cardiovascular disease

blood pressure levels.

medications,

years with

among Hispanics and

blood pressure

African Americans with

medications,

type 2 diabetes and

25(OH)D,

hypovitaminosis D

vitamin D

(<30 ng/ml).

intake, sun
exposure.
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time.

CHAPTER II: METHODS
The clinical trial conducted by our laboratory entitled “The effect of vitamin D
supplementation on cardiovascular risk factors among Hispanics and African
Americans with type 2 diabetes” was approved by the Institutional Review Board
(IRB) at Florida International University (IRB Protocol Approval #: IRB-13-0155).

Recruitment of Subjects
Subjects were recruited from two clinics in Miami-Dade County, Florida
(Borinquen Health Care Center and Clinical Care Medical Center) from July 2011
to March 2013 using flyers explaining the purpose of the study,
inclusion/exclusion criteria and containing investigators’ emails and phone
numbers. The non-randomized study screened subjects based on the inclusion/
exclusion criteria described as follows:
Inclusion criteria:
▪

Serum vitamin D insufficiency [25(OH)D< 30 ng/ml];

▪

Age 30-70 years old;

▪

Hispanic or African American; and

▪

Having type 2 diabetes

Exclusion criteria:
▪

Taking vitamin D supplements other than standard multivitamin formula;

▪

Pregnant or lactating;

▪

Kidney disease (glomerular filtration rate lower than 30 ml/min/1.73m2,
stages 4-5) and kidney failure (defined as currently on dialysis).
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▪

Using insulin to manage blood glucose;

▪

Major psychiatric disorders;

▪

Cancer;

▪

HIV/AIDS; and

▪

Hepatitis

Enrollment and Intervention
All subjects signed an informed consent in Spanish or English based on their
preference prior to participation in the study. Participants in both intervention
groups were required to take either 4,000 IU or 6,000 IU of vitamin D3 given in
the form of a pill in a single daily dose. Subjects in the 4,000 IU/d group were
recruited first and intervention was provided. Subjects were included on a first
come, first served basis until the required calculated sample size was attained.
After recruitment for the 4,000 IU/d group was completed, we conducted the
recruitment for the 6,000 IU/d group. Hence, group selection was not conducted
randomly and did not run in parallel. The number of subjects in the 6,000 IU/d
group was reduced to the minimum sample size required to find significant
differences in the main outcome variables.

Ninety-two participants were screened [4,000 IU/d group (n= 63) and 6,000
IU/d group (n= 29)]. Sixty-three qualified for the study and were enrolled for the
vitamin D3 intervention [4,000 IU/d group (n=39) and (6,000 IU/d (n=24)]. Four
participants were lost to follow-up after baseline [4,000 IU/d group (n=1) and

15

6,000 IU/d group (n=3)]. Additionally, two participants were lost to follow-up after
the 3 months’ assessment in the 6,000 IU/d group (Figure 1). Participants CKD
stages at baseline: (n=45, 71.0%) CKD stage 1 (≥ 90 eGFR ml/min/1.73 m2);
(n=15, 24%) CKD stage 2 (60-89 eGFR ml/min/1.73 m2); (n=3, 5.0%) CKD stage
3 (30-59 eGFR ml/min/1.73 m2). The study used an intent to treat approach, all
63 subjects were included in the statistical analysis. Each participant was seen 4
times during the study (screening, baseline, 3 and 6 months). Table 1 describes
assessments and assays conducted at each visit.
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Figure 1. Flow Diagram Showing Recruitment and Follow-Up of Participants

Abbreviations: AA= African Americans; H= Hispanics.
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Table 1. Assessments Frequency
Activity
Blood collection and analysis: serum 25(OH)D, PTH, creatinine,
cystatin C, hs-CRP, FPG and A1c
Urine: albumin and creatinine
Anthropometrics: height, weight and BMI
Demographics, FFQ & blood pressure
Sun Exposure: (Skin Color - reflectance colorimetry using the IMS
SmartProbe 400)
Determine medications for diabetes and hypertension and monitor
medication changes
Study adherence/compliance: pill count and compliance
Monitor safety and toxicity
Vitamin D3 (cholecalciferol) supplements distribution

S B 3
X

6

X X

X
X X
X
X X
X X X X
X X X X
X X X X
X X X
X X X
X X

Abbreviations: 25(OH)D= 25-hydroxy vitamin D, PTH= parathyroid hormone, hs-CRP=
High-sensitivity C-reactive Protein, A1C= hemoglobin A1c, FFQ= food frequency
questionnaire, (S)=screening, (B)=baseline.

Safety of the Intervention and Monitoring
Participants were monitored monthly for any symptoms of vitamin D3 toxicity
(nausea, vomiting, polyuria, polydipsia, weakness, nervousness, etc.) by
telephone, and at each follow-up visit that measured serum 25(OH)D levels.
Study adherence and compliance was assessed using serum 25(OH)D and PTH
levels change, pill count and attendance of scheduled visits at the clinics.
Compliance to the vitamin D3 supplementation was defined as taken more than
80% of the pills. To facilitate reporting to the clinics at data collection times, a
modest compensation for time and travel and laboratory reports were provided. A
Data Safety Monitoring Board (DSMB) monitored the safety of vitamin D3
supplementation every 12 month intervals for two years. This included evaluation
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of participant’s enrollment, follow-up visits, compliance, laboratory results, and
data management.

Vitamin D3 Supplements
Vitamin D3 (cholecalciferol) supplements at 4,000 IU and 6,000 IU were
custom manufactured by Biotech Pharmacal, Inc. (Fayetteville, AZ, U.S.) in a
single batch for each strength to avoid variation between lots. Since there was a
three-year expiration date, participants received the same 4,000 IU or 6,000 IU
lots accordingly. A certificate of Analysis was provided by the manufacturer to
assure that the product meets research specifications.

Blood Collection
Fasting venous blood (20 ml) was collected from each participant by a
certified phlebotomist using standard laboratory methods. After coagulation,
blood was centrifuged at 2500 RPM for 30 minutes. Solstas Lab Partners, Davie,
FL, U.S. performed blood and urine analyses using the standard procedures as
outlined.

Serum 25(OH)D levels were measured with an enzyme-immunoassay kit by
absorbance (Immunodiagnostic Systems; Scottsdale, AZ, U.S.), where the color
intensity is proportional to the concentration of 25(OH)D.
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Parathyroid Hormone was tested by a two-sided ELISA (Enzyme-Linked
ImmonoSorbent Assay) for the measurement of the biologically active 84 amino
acid chain of PTH.

Hemoglobin A1c was measured from whole blood samples using the Roche
Tina Quant methods and fasting plasma glucose was measured by hexokinase
enzymatic methods by Solstas Lab Partners, Davie, FL, U.S.

Creatinine (Serum) was measured using the Roche enzymatic method (RocheHitachi P-Module instrument with Roche Creatininase Plus assay, Roche Applied
Science, IN, U.S.).

Cystatin C (Serum) was measured in serum using an enzyme-linked
immunosorbent assay (ELISA) method (BioVendor LLC, NC, U.S.).

High Sensitivity-CRP (hs-CRP) was analyzed by Immulite (Diagnostic Products
Corporation, Los Angeles, CA). The Immulite assay is a 2-site chemiluminescent
enzyme immunometric assay with one monoclonal and one polyclonal anti-CRP
antibody.

Urine Collection
Fresh, single-voided, first morning urine samples were collected from each
participant to determine the following biomarkers of kidney function.

20

Urinary Albumin: Albumin was determined by immunoturbidmetric assay using
the Beckman Coulter microalbumin reagent with polyclonal antiserum. Turbidity
was measured at 340nm and 700nm on a spectrophotometer and albumin was
quantitatively determined using calibration curves. The immunoturbidometric
assay has been established as high sensitivity and high selectivity method for
detection of urinary albumin in normal and abnormal ranges for persons with
diabetes.

Creatinine (Urine): This procedure is a modification of the Jaffe method in which
creatinine reacts with picric acid at alkaline pH to form a yellow orange complex.
Color intensity is measured against a standard curve.

Estimation of Glomerular Filtration Rate (GFR)
Glomerular Filtration Rate equations were calculated using the online calculator
from the National Kidney Foundation
http://www.kidney.org/professionals/KDOQI/gfr_calculator). The online calculator
takes into consideration both serum creatinine and serum cystatin C
concentrations (CKD-EPI creatinine and CKD-EPI creatinine - cystatin C) as well
as age, gender, and race.
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Sociodemographic Data were collected with trained, bilingual interviewers
(English/ Spanish). Subjects were asked to complete a sociodemographic
questionnaire which included questions related to gender, age, education,
income, employment status, health insurance, smoking, and medications.

Vitamin D Intake
A short food frequency questionnaire containing 22 foods and beverages
designed to assess vitamin D and calcium intake was administered. The
questionnaire included participants’ frequency of consumption of each food and
the serving size. Total vitamin D intake was calculated following the original
rubric (Blalock et al., 2003).

Anthropometric Measures
Height and weight were measured using a Seca balance scale with
stadiometer (Seca Corp, Columbia, MD, U.S.). Body mass index (BMI) was
calculated as weight in kg/height in m2. Waist circumference to the nearest 0.1
cm was measured horizontally with a non-stretchable measuring tape placed
midway between the 12th rib and iliac crest at minimal respiration to determine
central obesity (NHLBI, 1998). Each measurement was taken twice and
averaged.
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Sun Exposure – (Skin Color)
Skin color was determined by reflectance colorimetry using the IMS
SmartProbe 400, Milford, CT. The instrument uses the International Commission
on Illumination Scale which ranges from 0 (black) to 100 (white) for skin color.
Two readings for each participant were taken, one on the right-hand wrist (area
most exposed to the sun) and other under the right upper arm (area least
exposed to the sun). The differences between the two measures were
determined to calculate the delta of skin color due to sun exposure.

Statistical Analysis
All data analyses were conducted on an “intent to treat” basis. Normal
distribution of all continuous variables was assessed using Shapiro-Wilk test.
Data was reported as means with standard deviation for continuous variables
and count and percentages for categorical variables. Independent t-test
(parametric) or Mann-Whitney U-test (non-parametric) for continuous variables
and chi-square test for categorical variables were used to compare differences in
baseline characteristics of participants across the two intervention groups (4,000
IU/d vs. 6,000 IU/d). Paired t-test was used evaluated pre- and post-intervention
(time effect) for normally distributed variables and Wilcoxon signed-rank test was
used for non-normally distributed variables for each study group.

Results from aims 1 and 2 were reported as mean with standard error. Linear
mixed models were performed using, 25(OH)D levels, estimated glomerular
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filtration rate (eGFR) equations, microalbuminuria, systolic and diastolic blood
pressure levels as the dependent variables, respectively. The interaction
between time and intervention was included to evaluate the dosage effect on the
change of the dependent variables over time. Least Significant Difference (LSD)
comparisons test were used to detect significant differences within and between
4,000 IU/d and 6,000 IU/d groups from baseline, 3 and 6 months on the outcome
variables without and with the adjustment of confounders. Linear mixed models
included the adjustment variables that were major confounders of serum
25(OH)D, kidney function and cardiovascular disease. Potential additional
covariates were tested by correlation with the dependent variable. Adjustment
variables included: age; gender; BMI; duration of diabetes; hemoglobin A1c;
vitamin D intake; sun exposure; serum vitamin D; and medication(s) usage.
Covariates that were related to outcomes were included as needed. The
analyses were conducted using SPSS software (SPSS Inc., Chicago, IL, U.S.)
version 23. All tests were analyzed two-sided and a significance level of <0.05
was used to decide the statistical significance.

Sample Size and Power Analysis
A statistical power analysis was performed using PASS 15 (Power Analysis
and Sample Size) 2017 Statistical Software (UT, U.S.) for Mixed Models, withinbetween groups interaction. Given an alpha of 0.05, a sample size of n=63 (n=39
for the group 4,000 IU/d and n=24 for the 6,000 IU/d) will have 82.0% power to
detect difference in eGFR (CKD-EPI) creatinine from baseline to 6 months. Thus,
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the sample size of n=63 was more than adequate for the main outcome of this
study and allowed to adjust for possible confounding factors. Additionally, power
analyses were calculated for other outcomes in the study (Table 2).

Table 2. Outcomes Power Calculation
Sample
Outcomes

Power

Alpha
Size

25-hydroxy vitamin D

82.0%

57

0.05

eGFR (CKD-EPI creatinine)

82.0%

57

0.05

eGFR (CKD-EPI creatinine - cystatin C)

84.0%

57

0.05

Microalbuminuria

70.0%

57

0.05

Systolic Blood Pressure

84.0%

57

0.05

Diastolic Blood Pressure

79.0%

57

0.05

Abbreviations: eGFR= Estimated Glomerular Filtration Rate; CKD-EPI=Chronic
Kidney Disease Epidemiology.
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CHAPTER III: RESULTS
Baseline Comparisons of Vitamin D3 Intervention Groups
The participants in this study were 53.4±8.3 years old (4,000 IU/d group) and
55.0±10.3 years old (6,000 IU/d group), the majority were female in both groups
71.8% (4,000 IU/d group) and 58.3% (6,000 IU/d group) respectively. The mean
known duration of diabetes was 6.1±4.7 years in the 4,000 IU/d group and
6.8±6.4 years in the group receiving 6,000 IU/d, and BMI above 30 kg/m2 in both
intervention groups classified them in the obesity category. All participants
started the study with serum 25(OH)D levels considered as deficient/insufficient
(20.7±6.0 ng/mL in the 4,000 IU/d group and 21.7±5.6 ng/mL in the 6,000 IU/d
group). At baseline, participants at the 4,000 IU/d group had significantly lower
systolic blood pressure levels (126.9±18.2 mmHg) and diastolic blood pressure
levels (82.3±10.7 mmHg) as compared with those in the 6,000 IU/d group
[(146.2±22.1 mmHg, p<.001) and (91.9±10.9 mmHg, p=0.001) respectively]. The
4,000 IU/d group had lower percentage of smokers (7.7% vs. 25.0%, p=0.057)
and higher serum creatinine levels (0.92±0.24 mg/dL vs. 0.80±0.20 mg/dL,
p=0.066) as compare with the 6,000 IU/d group. Participants in the 4,000 IU/d
group had significantly lower CKD-EPI creatinine values (84.6±18.4 mL/min)
compared with those in the 6,000 IU/d group (94.2±17.5 mL/min, p=0.027)
(Table 1).
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Table 1. Baseline Comparisons of Vitamin D3 Intervention Groups
Intervention
4,000 IU/d 6,000 IU/d
Variables
n=39
n=24
P-Value
Age (years)
53.4±8.3
55.0±10.3
0.499
Sex (Female) n (%)
28(71.8)
14(58.3)
0.271
BMI (kg/m2)
34.7±7.6
32.7±6.0
0.492
Waist circumference (cm)
109.6±18.6 107.3±12.4
0.388
Known years with diabetes
6.1±4.7
6.8±6.4
0.983
Smoking (yes) n (%)
3(7.7)
6(25.0)
0.057
Marital Status (married, yes) n (%)
22(56.4)
11(45.8)
0.862
Employment (yes) n (%)
22(56.4)
15(62.5)
0.383
Medical insurance (yes) n (%)
19(48.7)
11(45.8)
0.824
Diabetes medications (yes) n (%)
36(92.3)
22(91.7)
0.927
Blood pressure medications (yes) n (%)
26(66.7)
14(58.3)
0.505
Systolic blood pressure (mmHg)
126.9±18.2 146.2±22.1
<0.001
Diastolic blood pressure (mmHg)
82.3±10.7 91.9±10.9
0.001
Blood Biomarkers
25(OH)D (ng/mL)
20.7±6.0
21.7±5.6
0.457
PTH (pmol/L)
39.4±19.5 42.6±16.5
0.322
Insulin (μU/mL)
14.1±14.1
11.5±7.2
0.697
FGP (mg/dL)
189.0±88.7 184.4±71.6
0.944
A1c (%)
8.4±2.3
8.8±2.2
0.282
Hs-CRP (mg/L)
9.7±13.4
5.7±4.0
0.860
Cystatin C (mg/L)
0.70±0.19 0.70±0.25
0.865
Serum creatinine (mg/dL)
0.92±0.24 0.80±0.20
0.066
Urinary Biomarkers
Creatinine (mg/dL)
127.6±57.8 131.9±65.0
0.777
MAU (mg/dL)
4.5±15.2
6.9±15.1
0.152
Estimated GFR Equations
CKD-EPI creatinine (mL/min)
84.6±18.4 94.2±17.5
0.027
CKD-EPI creatinine - cystatin C
112.6±21.5 114.0±23.2
0.112
(mL/min)
Sun exposure
Upper arm skin color
58.9±9.8
60.4±7.3
0.837
Forearm skin color
55.2±8.7
56.6±6.0
0.915
Delta of skin color
3.7±3.6
3.9±5.0
0.510
Dietary
Vitamin D intake (IU/d)
127.0±82.7 122.2±86.4
0.692
Multivitamins (yes) n (%)
9(23.1)
5(20.8)
0.835
Alcohol intake n (%)
0.781
None
28(71.8)
18(75.0)
1 or more servings per week
11(28.2)
6(25.0)
Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D;
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose;
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MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.

Paired Comparisons of Vitamin D3 at 4,000 IU from Pre- to PostIntervention
Findings from paired comparisons of vitamin D3 at 4,000 IU/d from pre- to postinterventions are shown in Table 2. Serum 25(OH)D levels significantly
increased from baseline (20.7±6.0 ng/mL) to 6 months (37.9±13.2 ng/mL,
p<0.001). Cystatin C levels were significantly different from baseline (0.70±0.19
mg/L) to 6 months (0.79±0.28 mg/L, p=0.045). Serum creatinine levels
significantly decreased from baseline (0.92±0.24 mg/dL) to 6 months (0.83±0.25
mg/dL, p=0.001). CKD-EPI creatinine values significantly increased from
baseline (84.6±18.4 mL/min) to 6 months (92.4±18.9 mL/min, p<0.001). On the
other hand, CKD-EPI creatinine - cystatin C values significantly decreased from
baseline (112.6±21.5 mL/min) to 6 months (98.6±24.0 mL/min, p=0.022) (Table
2).
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Table 2. Paired Comparisons of Vitamin D3 at 4,000 IU from Pre- to PostIntervention

Variables
BMI (kg/m2)
Waist circumference (cm)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Blood biomarkers
25(OH)D (ng/mL)
PTH (pmol/L)
Insulin (μU/mL)
FGP (mg/dl)
A1c (%)
Hs-CRP (mg/L)
Cystatin C (mg/L)
Serum creatinine (mg/dL)
Urinary biomarkers
Creatinine (mg/dL)
MAU (mg/dL)
Estimated GFR Equations
CKD-EPI creatinine (mL/min)
CKD-EPI creatinine - cystatin C
(mL/min)
Sun exposure
Upper arm skin color
Forearm skin color
Delta of skin color
Dietary
Vitamin D intake (IU/d)

Intervention (4,000 IU/d)
n=39
Baseline
6 months
34.7±7.6
35.4±7.5
109.6±18.6
109.0±17.8
126.9±18.2
127.9±17.0
82.3±10.7
83.5±9.1

P-Value
0.136
0.913
0.690
0.459

20.7±6.0
39.4±19.5
14.1±14.1
189.0±88.7
8.4±2.3
9.7±13.4
0.70±0.19
0.92±0.24

37.9±13.2
37.2±17.8
11.4±8.1
170.1±73.6
8.2±2.1
7.4±7.0
0.79±0.28
0.83±0.25

<0.001
0.149
0.267
0.133
0.787
0.602
0.045
0.001

127.6±57.8
4.5±15.2

143.3±67.8
3.4±9.0

0.500
0.816

84.6±18.4
112.6±21.5

92.4±18.9
98.6±24.0

<0.001
0.022

58.9±9.8
55.2±8.7
3.7±3.6

59.3±9.9
55.5±8.6
3.8±4.2

0.346
0.827
0.971

127.0±82.7

132.8±90.4

0.913

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D;
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose;
MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.
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Table 3 shows findings from paired comparisons of vitamin D3 at 6,000 IU/d
from pre- to post- intervention. Systolic blood pressure levels (146.2±22.1
mmHg) significantly decreased from baseline to 6 months (135.0±17.8 mmHg,
p=0.009) and diastolic blood pressure marginally decreased (91.9±10.9 mmHg to
87.9±10.7 mmHg, p=0.077). Serum 25(OH)D levels significantly increased from
baseline (21.7±5.6 ng/mL) to 6 months (38.9±16.3 ng/mL, p<0.001). Serum
creatinine levels significantly decreased from baseline (0.80±0.20 mg/dL) to 6
months (0.74±0.20 mg/dL, p=0.004). CKD-EPI creatinine values significantly
increased from baseline (94.2±17.5 mL/min) to 6 months (97.9±18.0 mL/min,
p=0.047). There were marginally significant differences from baseline (56.6±6.0)
to 6 months (57.0±6.6, p=0.077) in forearm sun exposure scores.
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Table 3. Paired Comparisons of Vitamin D3 at 6,000 IU from Pre- to PostIntervention
Intervention (6,000 IU/d)
n=24
Variables
BMI (kg/m2)
Waist circumference (cm)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Blood biomarkers
25(OH)D (ng/mL)
PTH (pmol/L)
Insulin (μU/mL)
FGP (mg/dl)
A1c (%)
Hs-CRP (mg/L)
Cystatin C (mg/L)
Serum creatinine (mg/dL)
Urinary biomarkers
Creatinine (mg/dL)
MAU (mg/dL)
Estimated GFR Equations
CKD-EPI creatinine (mL/min)
CKD-EPI creatinine - cystatin C
(mL/min)
Sun exposure
Upper arm skin color
Forearm skin color
Delta of skin color
Dietary
Vitamin D intake (IU/d)

Baseline

6 months

32.7±6.0
107.3±12.4
146.2±22.1
91.9±10.9

33.1±6.3
102.7±24.9
135.0±17.8
87.9±10.7

PValue
0.970
0.404
0.009
0.077

21.7±5.6
42.6±16.5
11.5±7.2
184.4±71.6
8.8±2.2
5.7±4.0
0.70±0.25
0.80±0.20

38.9±16.3
38.3±17.3
11.4±7.1
180.7±73.9
8.6±2.0
7.4±7.1
0.75±1.9
0.74±0.20

<0.001
0.052
0.577
0.697
0.139
0.270
0.365
0.004

131.9±65.0
6.9±15.1

117.1±48.4
7.0±14.2

0.306
0.370

94.2±17.5
114.0±23.2

97.9±18.0
107.4±20.1

0.047
0.270

60.4±7.3
56.6±6.0
3.9±5.0

61.1±6.5
57.0±6.6
4.2±4.6

0.173
0.072
0.417

122.2±86.4

115.9±82.9

0.638

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D;
PTH=parathyroid hormone; A1c=glycated hemoglobin; FPG=fasting plasma glucose;
MAU=microalbuminuria; GFR= Glomerular filtration rate; CKD-EPI=Chronic Kidney
Disease Epidemiology Collaboration; d=day; SD= standard deviation. Data reported as
Mean±SD; unless otherwise indicated. P is considered significant at <0.05.
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Aim 1: To evaluate the effect of vitamin D3 supplementation (cholecalciferol) at
6,000 IU/d vs. 4,000 IU/d on kidney function among Hispanics and African
Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml).

Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
raising 25(OH)D levels from deficient/insufficient to sufficient as compared to
4,000 IU/d over 6 months.

Unadjusted linear mixed models indicated statistically significant effect of
time on serum 25(OH)D levels (p<0.001). However, the effect of intervention
(p=0.294) and interaction between time and intervention (p=0.120) were not
statistically significant. Post-hoc LSD analyses showed significant improvements
in serum 25(OH)D levels over time in both intervention groups. In the 4,000 IU/d
and 6,000 IU/d groups respectively, significant increase in serum 25(OH)D levels
were observed from baseline [(20.7±0.9 ng/mL) and (21.7±1.2 ng/mL)] to 3
months [(37.0±2.1 ng/mL, p<0.001) and (42.6±2.6 ng/mL, p<0.001)] and to 6
months [(37.9±2.3 ng/mL, p<0.001) and (38.9±2.9 ng/mL, p<0.001)] respectively
(Table 4).
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Table 4. Unadjusted and Adjusted Intervention Groups Comparisons of 25(OH)D at Different Time Points
Intervention
4,000 IU/d
6,000 IU/d
Unadjusted
n=39
n=24
25(OH)D (ng/mL)
Mean±SE
Baseline
20.7±0.9
21.7±1.2
3 months
37.0±2.1*
42.6±2.6*
6 months
37.9±2.3*
38.9±2.9*
P-value time=0.001
P-value intervention=0.294
P-value interaction=0.120
Adjusted
25(OH)D (ng/mL)
Baseline
3 months
6 months
P-value time=0.001

Mean±SE
19.8±1.1
21.4±1.2
36.1±2.2*
43.0±2.7*; **
37.1±2.4*
39.2±3.0*
P-value intervention=0.143
P-value interaction=0.088

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; SE=standard error.
*Represents significant differences from baseline; **represents significant differences from 3 to 6 months.
Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure
medications, 25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.
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Adjusted linear mixed models after including covariates in the analysis, a
statistically significant effect of time on 25(OH)D levels (p<0.001) was observed.
However, the effect of intervention between groups was not statistically
significant (p<0.143). There was a marginally significant result for the interaction
between time and intervention (p=0.088). In the 4,000 IU/d and 6,000 IU/d
groups, a significant increase in serum 25(OH)D levels were observed from
baseline [(19.9±1.1 ng/mL) and (21.4±1.3 ng/mL)] to 3 months [(36.1±2.2 ng/mL,
p<.001) and (43.0±2.7 ng/mL, p<0.001)] and 6 months [(37.1±2.4 ng/mL,
p<0.001) and (39.2±3.0 ng/mL, p<0.001)], respectively. Moreover, in the 6,000 IU
group, there was a significant decrease in serum 25(OH)D levels from 3 months
(43.0±2.7 ng/mL) to 6 months (39.2±3.0 ng/mL, p=0.046) (Table 4).

Hypothesis 2: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
increasing eGFR using CKD-EPI creatinine when compared to 4,000 IU/d over 6
months.

Unadjusted linear mixed models showed that the effect of time on CKD-EPI
creatinine was statistically significant (p<0.001), intervention effect was
marginally significant (p=0.067); however, the interaction between time and
intervention was not statistically significant (p=0.110). Post-hoc LSD analyses
showed that there was a marginally significant increase in CKD-EPI creatinine
values from baseline (84.6±2.8 mL/min) to 3 months (88.0±2.9 mL/min, p=0.077)
and significant increase in CKD-EPI creatinine values to 6 months (92.5±2.9
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mL/min, p<0.001) in the 4,000 IU/d group. Moreover, significant increase was
found from 3 months to 6 months (p=0.004) in the 4,000 IU/d group. In the 6,000
IU/d group, marginally significant increase in mean CKD-EPI creatinine were
observed from baseline (94.2±3.6 mL/min) to 6 months (97.9±3.7 mL/min,
p=0.082).

Adjusted linear mixed models indicated that the effect of time (p<0.001) on
CKD-EPI creatinine was statistically significant. However, the intervention effect
(p=0.0162) and the interaction effect of time and intervention were not statistically
significant (p=0.121). Post-hoc analysis showed marginally significant increase in
CKD-EPI creatinine values from baseline (83.8±3.2 mL/min) to 3 months
(88.0±3.0 mL/min, p=0.074) and statistically significant increase to 6 months
(93.0±3.1 mL/min, p<0.001) in the 4,000 IU/d group. Moreover, significant
improvements in CKD-EPI creatinine values were also observed from 3 months
(88.0±3.0 mL/min) to 6 months (93.0±3.1 mL/min, p=0.002) in the 4,000 IU/d
group. Marginally significant increase in mean CKD-EPI creatinine values from
baseline (90.1±3.9 mL/min) to 6 months (96.0±3.9 mL/min, p=0.059) were found
in the 6,000 IU/d group (Table 5).
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Table 5. Unadjusted and Adjusted Intervention Groups Comparisons of CKD-EPI creatinine at Different Time
Points
Intervention
4,000 IU/d
6,000 IU/d
Unadjusted
n=39
n=24
CKD-EPI creatinine (mL/min)
Mean±SE
Baseline
84.6±2.8
94.2±3.6
;
3 months
88.0±2.9* **
97.7±3.7
6 months
92.5±2.9*
97.9±3.7
P-value time<0.001
P-value intervention=0.067
P-value interaction=0.110
Adjusted
CKD-EPI creatinine (mL/min)
Baseline
3 months
6 months
P-value time<0.001

Mean±SE
83.8±3.2
88.0±3.0*; **
93.0±3.2*
P-value intervention=0.162

91.0±3.9
96.0±3.8
96.0±3.9
P-value interaction=0.095

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; CKD-EPI=Chronic
Kidney Disease Epidemiology Collaboration; SE=standard error. *Represents significant differences from baseline;
**represents significant differences from 3 to 6 months.
Adjustment variables: BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications, 25(OH)D,
vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.
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Hypothesis 3: Vitamin D3 supplementation at 6,000 IU/d will be more effective in
increasing eGFR using CKD-EPI creatinine - cystatin C when compared to 4,000
IU/d over 6 months.

Unadjusted linear mixed models showed that the effect of time on CKD-EPI
creatinine - cystatin C was statistically significant (p<0.011). However, the
effect of intervention (p=0.105) or the interaction between time and intervention
(p=0.636) were not statistically significant. LSD post-hoc analyses showed a
significant decrease in CKD-EPI creatinine - cystatin C values from baseline
(104.9±3.4 mL/min) to 6 months (97.6±3.2 mL/min, p=0.029) and from 3 months
(106.7±3.5 mL/min) to 6 months (97.6±3.2 mL/min, p=0.002) in the 4,000 IU/d
group. Additionally, changes in CKD-EPI creatinine - cystatin C values between
intervention groups (4,000 IU/d vs. 6,000 IU/d) at 6 months were observed at the
marginal significance level (97.6±3.2 mL/min vs. 107.4±4.1 mL/min, p=0.066)
(Table 6).

Adjusted linear mixed models indicated that the effect of time on CKD-EPI
creatinine - cystatin C values were statistically significant (p=0.020). However,
the effect of intervention (p=0.289) and time and intervention interaction
(p=0.740) were not statistically significant. LSD post-hoc analyses showed a
significant decrease in CKD-EPI creatinine - cystatin C values from 3 months
(109.2±3.9 mL/min) to 6 months (100.9±3.7 mL/min, p=0.006) in the 4,000 IU/d
group.
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Table 6. Unadjusted and Adjusted Intervention Groups Comparisons of CKD-EPI creatinine - cystatin C at
Different Time Points
Intervention
4,000 IU/d
6,000 IU/d
Unadjusted
n=39
n=24
CKD-EPI creatinine - cystatin C
Mean±SE
(mL/min)
Baseline
104.9±3.4
112.6±4.3
3 months
106.7±3.5**
112.2±4.5
6 months
97.6±3.2*
107.4±4.1
P-value time=0.011
P-value intervention=0.105
P-value interaction=0.636
Adjusted
CKD-EPI creatinine-cystatin C
(mL/min)
Baseline
3 months
6 months
P-value time=0.020

Mean±SE
106.0±4.3
109.2±3.9**
100.9±3.7
P-value intervention=0.289

110.4±4.9
112.4±4.7
107.1±4.3
P-value interaction=0.830

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; CKD-EPI=Chronic
Kidney Disease Epidemiology Collaboration; SE=standard error. *Represents significant differences from baseline;
**represents significant differences from 3 to 6 months.
Adjustment variables: BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications,
25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.
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Hypothesis 4: Vitamin D3 supplementation at 6,000 IU/d will be more effective
than the 4,000 IU/d over 6 months in lowering microalbuminuria measured by
first morning urine samples.

Unadjusted and Adjusted linear mixed models showed that the effect of
time [(p=0.889) and (p=0.954)], intervention [(p=0.254) and (p=0.425)] and the
interaction between time and intervention [(p=0.370 and (p=0.435)] on
microalbuminuria were not statistically significant within and between 4,000
IU/d and 6,000 IU/d groups, respectively (Table 7).
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Table 7. Unadjusted and Adjusted Intervention Groups Comparisons of Microalbuminuria at Different Time
Points
Intervention
4,000 IU/d
6,000 IU/d
Unadjusted
n=39
n=24
MAU (mg/dL)
Mean±SE
Baseline
4.5±2.4
6.8±3.0
3 months
3.1±1.9
8.1±2.5
6 months
3.5±1.8
7.0±2.3
P-value time=0.889
P-value intervention=0.254
P-value interaction=0.370
Adjusted
MAU (mg/dL)
Baseline
3 months
6 months
P-value time=0.954

Mean±SE
4.5±2.9
3.5±2.3
3.9±2.2
P-value intervention=0.425

5.9±3.5
7.5±2.8
6.7±2.5
P-value interaction=0.435

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; MAU=microalbuminuria;
SE=standard error.
Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure medications,
25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.05.
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Aim 2: To evaluate the effect of vitamin D3 supplementation at 6,000 IU/d vs.
4,000 IU/d on markers of cardiovascular disease risk among Hispanics and
African Americans with type 2 diabetes and hypovitaminosis D (<30 ng/ml).

Hypothesis 1: Vitamin D3 supplementation at 6,000 IU/d will be more effective
than the 4,000 IU/d over 6 months in lowering systolic and diastolic blood
pressure levels.

Unadjusted mixed models showed marginally significant effect of time
(p=0.080) and significant effect of intervention (p=0.001) on systolic blood
pressure. A significant effect of the interaction between time and intervention
(p=0.032) was observed. LSD post-hoc analyses indicated that systolic blood
pressure levels significantly decreased from baseline (146.2±4.0 mmHg) to 3
months (139.8±3.3 mmHg, p=0.035) and significantly higher decrease at 6
months (135.0±3.5 mmHg, p=0.003) only in the 6,000 IU/d vitamin D group.
Additionally, significant differences were observed in systolic blood pressure
levels between 4,000 IU/d and 6,000 IU/d groups at 3 months [(126.5±2.6 mmHg
vs. 139.8±3.3 mmHg, p=0.002)] (Table 8).

Adjusted linear mixed models showed no significant effect of time on
systolic blood pressure (p=0.490). However, the effect of intervention
(p=0.006) and the interaction between time and intervention (p=0.026) were
statistically significant. Post-hoc LSD analyses showed a significant decreased in
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mean systolic blood pressure levels from baseline (144.1±4.0 mmHg) to 6
months (134.5±3.5 mmHg, p=0.020) only for the 6,000 IU/d group. Furthermore,
a marginal decrease in systolic blood pressure levels were observed in the 6,000
IU/d group from 3 months (139.9±3.4 mmHg) to 6 months (134.5±3.5 mmHg,
p=0.088). Significant differences between intervention groups (4,000 IU/d vs.
6,000 IU/d) in systolic blood pressure levels were found at 3 months (128.5±2.6
mmHg vs. 139.9±3.4 mmHg, p=0.007) but not in 6 months (Table 8).

Unadjusted mixed models indicated that the effect of intervention on
diastolic blood pressure was statistically significant (p=0.003). However, the
effect of time (p=0.538) or the interaction between time and intervention
(p=0.110) were not statically significant. LSD post-hoc analyses indicated that
changes in diastolic blood pressure levels were marginally significant from
baseline (91.8±2.2 mmHg) to 6 months (87.9±2.0 mmHg, p=0.055) in the 6,000
IU/d group. Additionally, significant differences in mean diastolic blood pressure
levels were observed at 3 months (83.2±1.5 mmHg vs. 89.3±1.9 mmHg,
p=0.015) and marginally significant at 6 months (83.5±1.5 mmHg vs. 87.9±2.0
mmHg, p=0.086) (Table 8).

Adjusted linear mixed models analysis showed that the effect of
intervention on diastolic blood pressure was statistically significant (p=0.004);
however, the effect of time (p=0.703) or the interaction of between time and
intervention (p=0.108) were not significant. Post-hoc LSD analyses revealed
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marginally significant decrease in mean diastolic blood pressure levels from
baseline values (91.3±2.6 mmHg) to 6 months (87.3±2.2 mmHg, p=0.086) only
for the 6,000 IU/d group. Significant differences between intervention groups
(4,000 IU/d vs. 6,000 IU/d) in diastolic blood pressure levels were observed at 3
months (82.7±1.9 mmHg vs. 88.7±2.2 mmHg, p=0.017) (Table 8).
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Table 8. Unadjusted and Adjusted Intervention Groups Comparisons of Blood Pressure at Different Time
Points
Intervention
4,000 IU/d
6,000 IU/d
Unadjusted
n=39
n=24
Systolic blood pressure (mmHg)
Mean±SE
Baseline
126.8±3.1
146.2±4.0
†
3 months
126.5±2.6
139.8±3.3*
6 months
127.9±2.7
135.0±3.5*
P-value time=0.080
P-value intervention=0.001
P-value interaction=0.032
Diastolic blood pressure (mmHg)
Baseline
82.3±1.7
91.8±2.2
3 months
83.2±1.5†
89.3±1.9
6 months
83.5±1.5
87.9±2.0
P-value time=0.538
P-value intervention=0.003
P-value interaction=0.110
Adjusted
Systolic blood pressure (mmHg)
Baseline
3 months
6 months
P-value time=0.490
Diastolic blood pressure (mmHg)
Baseline
3 months
6 months
P-value time=0.703

Mean±SE
127.1±3.3
144.1±4.0
128.5±2.6†
139.9±3.4
130.3±2.8
134.5±3.5*
P-value intervention=0.006
P-value interaction=0.026
81.7±2.2
82.7±1.9†
82.9±1.9
P-value intervention=0.004

91.3±2.6
88.7±2.2
87.3±2.2
P-value interaction=0.108

Abbreviations: BMI= body mass index; 25(OH)D=25-hydroxy vitamin D; A1c=glycated hemoglobin; SE=standard error.
*Represents significant differences from baseline; † represents significant differences at 3 months between intervention
groups. Adjustment variables: age gender, BMI, known years with diabetes, A1c, diabetes medications, blood pressure
medications, 25(OH)D, vitamin D intake, sun exposure. Data reported as Mean±SE. P is considered significant at <0.050.
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CHAPTER IV: DISCUSSION
Serum 25-hydroxy vitamin D
The study focused on vitamin D3 supplementation interventions for Hispanics
and Blacks with hypovitaminosis D and type 2 diabetes. All participants in our
study had 25(OH)D levels below 30 ng/mL at baseline. Our findings showed that
vitamin D3 supplementation noticeably increased 25(OH)D levels in both
intervention groups which indicated that the supplement doses were adequately
bioavailable, well absorbed and tolerated by the participants. It was expected that
serum 25(OH)D levels would improve at 6 months in both groups; however, we
found no significant differences between the 4,000 IU/d and 6,000 IU/d groups at
the end of the study. Despite the high doses of vitamin D3 used in this study,
there were no adverse events or signs of toxicity reported by any of the
participants throughout the study.

Several previous studies are available where vitamin D3 (cholecalciferol) was
used to replenish serum 25(OH)D levels. Kim et al. (2011), used
supplementation with vitamin D3 for participants with serum vitamin D deficiency
(≤ 16 ng/ml) with 40,000 IU/week for 8 weeks and 40,000 IU/month for additional
8 weeks; and participants with vitamin D insufficiency (16-32 ng/mL) with 40,000
IU/month. They found significantly increased mean serum 25(OH)D levels from
baseline (15.6±7.0 ng/mL) to 4 months (39.7±12.8 ng/ml) in individuals with type
2 diabetes. In our study, mean 25(OH)D levels at baseline were 20.7 ng/mL for
the 4,000 IU/d group and 21.7 ng/mL for the 6,000 IU/d. By the end of the
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intervention (6 months), mean 25(OH)D levels increased to sufficient levels 37.9
ng/mL for the 4,000 IU/d group and 38.9 ng/mL for the 6,000 IU/d group. In
another study, individuals were supplemented with the equivalent of 10,000 IU/d
for 3 months, mean 25(OH)D levels significantly increased (pre-intervention =
13.4 ng/mL to post-intervention = 82.8 ng/mL). Conversely, there are studies
where vitamin D3 supplementation did not replenish serum 25(OH)D levels above
(30 ng/mL). These studies used doses of vitamin D3 supplementation ≤ 1000 IU/d
or the equivalent (Oksa et al., 2008 and Rucker et al., 2009).

The Institute of Medicine (IOM) guidelines (Institute of Medicine, 2011)
specified that the Recommended Dietary Allowance (RDA) for >97.5% of the
population for vitamin D intake is 600-800 IU/d. In our study, none of the
participants met the RDA for vitamin D for their age, the mean vitamin D intake
was 127.0±82.7 IU for the 4,000 IU/d group and 122.2±86.4 IU for the 6,000 IU/d
group (Table 1). Nevertheless, greater dosages than the RDA of vitamin D
intake are needed it to replenish those with deficient and insufficient 25(OH)D
levels. We investigated the effect of vitamin D3 supplementation using the IOM
(Institute of Medicine, 2011) recommended tolerable upper intake level (4,000
IU/d) and a higher dose (6,000 IU/d); however, the IOM recommendations for
vitamin D are not formulated for those with preexisting conditions (such as
diabetes). The Endocrine Society Clinical Practice Guideline advise that
individuals with 25(OH)D levels below 20 ng/mL be supplemented with vitamin D3
(6,000 IU/d) for eight weeks to restore normal vitamin D levels above 30 ng/mL.
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After reaching sufficiency, vitamin D3 supplementation needs to be continued by
a maintenance phase of 1,500-2,000 IU/d. Due to the high prevalence of vitamin
D deficiency/insufficiency in individuals with type 2 diabetes, achieving normal
25(OH)D levels should be considered an important therapeutic goal. The amount
of vitamin D3 necessary to achieve adequate serum 25(OH)D levels for
populations with multiple chronic conditions has yet to be established and may
be confounded by variations in geographic region, seasons, skin color, sun
exposure, race/ethnicity, diet, and body fat. The optimal 25(OH)D level that
would have a clinical effect on health risk outcomes remains to be defined.

Our study did not include a placebo or control arm, since the intervention
groups were not recruited and conducted in parallel and due to the inclusion
criterion, we included individuals with 25(OH)D levels with
deficiency/insufficiency (<30 ng/mL). Ethically it was not appropriate or advisable
to treat vitamin D deficient/insufficient participants with placebo for 6 months.
Participants were not allowed to take any type or form of vitamin D supplement
other than a multivitamin, and we encouraged them to not change their dietary
and sun exposure habits during the study. The high doses of vitamin D3 used in
this study were not only intended to replenish serum 25(OH)D levels but also to
improve study outcomes (kidney and cardiovascular disease markers).
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Glomerular Filtration Rate (GFR)
Studies showed that diabetes and kidney disease are associated with low
25(OH)D levels (Husemoen et al., 2012; Levin et al., 2007). Existing data
indicate the relationship between hypovitaminosis D and mortality in individuals
with chronic kidney disease (CKD) (Navaneethan et al., 2011). CKD is a
predictor of vitamin D insufficiency/deficiency because the kidney is involved in
the metabolism of vitamin D (Echida et al., 2012). Findings from our study
suggest the possible beneficial role of vitamin D3 supplementation on kidney
function biomarkers in individuals with type 2 diabetes. Our study showed that
individuals with type 2 diabetes had significantly improved kidney function by
increasing CKD-EPI creatinine equation over time (pre-intervention = 84.6±18.4
mL/min – post-intervention = 92.4±18.9 mL/min) in the 4,000 IU/d group and
(pre-intervention = 94.2±17.5 mL/min to post-intervention = 97.9±18.0 mL/min) in
the 6,000 IU/d group. The effect of vitamin D3 supplementation on markers of
kidney function persisted after adjusting for major confounding variables only on
the 4,000 IU/d group. This could be due to small number of participants in the
6,000 IU/d group (n=24) and higher CKD-EPI creatinine values at baseline as
compared to the 4,000 IU/d. On the other hand, CKD-EPI creatinine - cystatin C
equation indicated significant decrease over time (pre-intervention = 112.6±21.5
mL/min to post-intervention = 98.6±24.0 mL/min) in the 4,000 IU/d group. There
are several possible explanations for the different results from the eGFR
equations. The study by Fan et al. (2014) compared the effectiveness of eGFR
equations: CKD-EPI creatinine and CKD-EPI creatinine - cystatin C. Results
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showed that CKD-EPI creatinine equation underestimated more individuals with
elevated BMI as compared to the CKD-EPI creatinine - cystatin C equation. The
CKD-EPI creatinine - cystatin C equation was more precise than CKD-EPI
creatinine while estimating GFR values for those with diabetes and obesity.
However, the study by Fan et al. (2014) have limitations. Pooled analyzed data
from that study cannot distinguish between individuals with type 1 or type 2
diabetes, the approaches used to estimate glomerular filtration rate, or factors
that affected creatinine values.

In a longitudinal study with a follow-up of over 4 years (n=1705) (De Boer et
at., 2011), lower 25(OH)D levels were linked a faster change in eGFR rate loss
among older adults, especially for those with 25(OH)D level below 15 ng/mL,
diabetes and hypertension. Vitamin D3 supplementation (666 IU/d) for 6 months
did not significantly change in eGFR values in either the intervention or control
group and non-significant differences were found between study groups with
CKD stages 3-4 (Molina et al., 2014). Vitamin D3 supplementation of 1000 IU/d
versus a control for Canadian adults with later stages (3-5) of kidney disease
study found no improvements in kidney function (GFR and albuminuria).
Negative findings could be due to the mean 25(OH)D levels post-intervention
being below the 30 ng/mL sufficiency and short duration of the supplementation
(3 months) (Rucker et al., 2009). Two additional studies by Kim et al. (2011) and
Basturk et al. (2011) found no significant changes in eGFR after vitamin D3
supplementation. All the studies reported included participants in the later stages
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of CKD 3-5 contrary to our study where we included participants with early
stages of CKD (1-3). Early supplementation with vitamin D3 might provide a more
valuable treatment and possibly delaying adverse kidney disease outcomes.

The National Kidney Foundation clinical guidelines indicated that individuals
with CKD stages 3-4 and serum 25(OH)D levels (<30 ng/mL) to be treated with
vitamin D2 instead of vitamin D3 (National Kidney Foundation, 2003). At the time
(year 2003) when this guideline was written no controlled clinical studies were
available comparing the safety and efficacy of vitamin D2 versus vitamin D3.
Additionally, access to commercial high doses up to 50,000 IU are available for
vitamin D2 (Houghton and Vieth, 2006). The dosage recommendation by the
National Kidney Foundation clinical guidelines is according to the vitamin D
status. Individuals with vitamin D deficiency [serum 25(OH)D levels (<5 ng/mL
and 5-15 ng/mL)] should receive 50,000 IU/week for 4-12 weeks and then same
dose monthly for 6 months. Individuals with vitamin D insufficiency [serum
25(OH)D levels 16-30 ng/mL)] should receive 50,000 IU/month for 6 months
(National Kidney Foundation, 2003). Nevertheless, previous studies
demonstrated that supplementation with vitamin D2 were less consistent in
reaching ideal serum 25(OH)D levels (> 30mg/mL) as compared to vitamin D3
(Houghton and Vieth, 2006; Armas et al., 2004; Heaney et al., 2011). Several
studies found a reduction in kidney disease markers using vitamin D analogues
(paricalcitol) (Alborzi et al., 2008; de Zeeuw et al., 2010; Fishbane et al., 2009);
however, vitamin D3 has been shown to be equally effective. The equal
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effectiveness of vitamin D3 may be of importance since hypercalcemia has been
observed with some vitamin D analogues (Moe et al, 2009). Vitamin D analogues
are biologically active and individuals using them need to be monitored for
hypercalcemia and hyperphosphatemia more closely than with vitamin D 3
(Kandula et al., 2011). There are no formal recommendations for vitamin D3
supplementation for individuals with early CKD by the National Kidney
Foundation. Still clarification and a more precise definition needs to be
implemented for the vitamin D3 supplementation dosage, frequency, serum
25(OH)D levels before intervention starts, and whether complications from kidney
dysfunction can be prevented. Therefore, available guidelines from Kidney
Disease Outcomes Quality Initiative (KDOQI) needs to be revised.

Current study contributes to the scientific knowledge for understanding of the
role of vitamin D3 supplementation on kidney function among minority groups.
Early interventions could delay progression of the disease which would have a
profound effect on lowering health care costs and burden to society as well as
improving the quality of life (Jungers, 2002). Medical costs were doubled for
individuals with kidney disease from a large Health Maintenance Organization
(HMO) as compared to those without kidney disease (Smith et al., 2004).
Therefore, approaches to manage kidney disease such as vitamin D 3
supplementation are important in clinical practice.
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Microalbuminuria
Reduction of urinary albumin levels is an important therapeutic goal that slow
the progression of kidney dysfunction. Previous studies indicated that
microalbuminuria was associated with cardiovascular disease and mortality in
individuals with type 2 diabetes (Mogensen, 1984; Valmadrid et al., 2000).
Microalbuminuria, abnormal increase in urinary albumin excretion, is an early
sign of kidney dysfunction (Mogensen, 1984). In a prospective population-based
study, individuals with type 2 diabetes (n=1,253) were followed for 7 years,
microalbuminuria was linked to a 42% increase in the progression to
nephropathy (Bruno et al., 2003). The usual course of microalbuminuria is
progressive in individuals with type 2 diabetes (Bruno et al., 2003); therefore,
early screening and treatment of microalbuminuria can reduce the risk for kidney
dysfunction and possibly decrease the burden associated with diabetes
complications.

Several studies found an inverse association between 25(OH)D levels and
albuminuria (de Boer et al., 2007; Skaaby et al., 2013; Isakova et al., 2011). Data
from NHANES III that included (n=15,068) participants, found an inverse
association between 25(OH)D levels and prevalence of albuminuria (de Boer et
al., 2007). Furthermore, after excluding participants with macroalbuminuria from
the statistical analysis, significant similar results were also found for
microalbuminuria (de Boer et al., 2007). In a five-year follow-up study of a
random sample of Caucasians (n=4,330), aged 30-60 years, low 25(OH)D levels
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predicted higher urinary protein excretion (Skaaby et al., 2013). Hypovitaminosis
D frequently occurs in minorities groups, especially in those with type 2 diabetes
and kidney dysfunction. The clinical implications of monitoring microalbuminuria
and 25(OH)D levels among individuals with type 2 diabetes may delay future
adverse complications, especially among individuals with other concomitant
conditions (i.e. hypertension).

In our study, microalbuminuria did not improve over time by either dose of
vitamin D3 supplementation. The findings from several studies corroborate our
study results. In a randomized, double blind, clinical trial, fifty-two individuals
[hemodialysis treated (n=27)/ non-hemodialysis treated (n=25)] with serum
25(OH)D levels <20 ng/mL received vitamin D3 supplementation (40,000
IU/week) or placebo. After 8 weeks, vitamin D3 supplementation did not
significantly change urinary protein excretion (Marckmann et al., 2012). Urinary
protein excretion showed no significant improvements in a Brazilian cohort
(n=45) with CKD stages 3-4 that were supplemented with vitamin D3 (50,000
IU/week) for 6 months (Garcia-Lopes et al., 2012). In contrast, several studies
described that vitamin D3 supplementation reduce albuminuria. In a prospective
study, individuals (n=63) with type 2 diabetes and CKD stages 2-4 were given
vitamin D3 supplementation according to their serum vitamin D status. Results
showed a reduction of albuminuria for those receiving vitamin D3
supplementation (Kim et al., 2011). In the study by Molina et al. (2014),
Caucasian older adult participants (n=101) with advance CKD (stages 3-4)
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received either vitamin D3 supplementation (666 IU/d) or placebo for 6 months.
Urinary albumin-to-creatinine ratio significantly decreased only in participants
who received vitamin D3 supplementation. Improving kidney function in
individuals with type 2 diabetes play a vital role in preventing cardiovascular
disease and development of end-stage renal disease (ESRD).

Blood Pressure
This study demonstrated that vitamin D3 supplementation improved systolic
blood pressure in the higher dose group (6,000 IU/d). Our study found a
reduction in systolic blood pressure of approximately 11 mmHg (pre-intervention=
146.2±22.1 mmHg – post-intervention= 135.0±17.8 mmHg) by the end of the 6
months’ intervention. Results of this study are consistent with some previous
studies. A randomized, double-blind, clinical trial investigated the effect oral
vitamin D3 cholecalciferol (50,0000 IU/per week) on blood pressure among
individuals with type 2 diabetes (n=30 intervention/ n=30 placebo). Thirty-two
participants in the study had either serum 25(OH)D levels classified as deficient
(n=5) or insufficient (n=27). Vitamin D3 supplementation (50,000 IU per week)
reduced systolic and diastolic blood pressure from baseline (121.0±13.0 mmHg
and 80.5±8.0 mmHg) to 12 weeks’ follow-up (110.0±9.0 mmHg, p=0.001 and
76.3±7.0 mmHg, p=0.046 respectively), only in the intervention group (Nasri et
al., 2014). The efficacy of 8 weeks of vitamin D3 (800 IU/d) and calcium
supplementation (1200 mg) vs. calcium supplementation (1200 mg/d) on blood
pressure was measured on elderly women (n=148) with 25(OH)D levels below
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(20 ng/mL). A significant reduction in systolic blood pressure of 9.3%
[(baseline=144.1±20.4 mmHg) and (8-week follow-up=131.0±16.9 mmHg)] was
found in the intervention with vitamin D3 and calcium group as compared to
calcium alone group [(baseline=140.6±14.7 mmHg) and (8-week follow-up=
134.9±19.9 mmHg)]; however, no significant decrease in diastolic blood pressure
was found (Pfeifer et al., 2001). Another study (Sugden et al., 2008) investigated
the effect of vitamin D2 (100,000 single oral dose) supplementation vs. placebo
on blood pressure in individuals with type 2 diabetes and low 25(OH)D (<20
ng/mL). After 8-week follow-up, participants in the vitamin D2 group (n=17) had
reduced systolic blood pressure by 14 mmHg compared to those in the placebo
group (n=17); however, no significant changes were found for diastolic blood
pressure.

In contrast, results from other studies found no improvements in blood
pressure after vitamin D3 supplementation. Findings from the DAYLIGHT trial, a
double-blind, randomized controlled study, which included (n=534) participants
with age range of 18-50 years old, 25(OH)D levels (≤ 25 ng/ml), and
prehypertension and/or untreated stage 1 hypertension indicated no beneficial
effect of vitamin D3 supplementation groups (400 IU/d or 4,000 IU/d) on systolic
or diastolic blood pressure after 6 months of intervention (Arora et al., 2014). This
study is one of the largest sampled (46% Whites, 48% Blacks and 6% other
ethnicity) clinical trial conducted were the primary endpoint was blood pressure.
In a randomized controlled, double-blind clinical trial, vitamin D3 supplementation
55

(a single oral dose of 100,000 IU) did not significantly reduce blood pressure
during the 5-week duration in elderly adults during winter (n=95 intervention
group, n=94 placebo group) (Scragg et al., 1995). Vitamin D3 supplementation
(Schleithoff et al., 2006) (intervention group, n=42, 2000 IU + Calcium 500 mg/d)
or (placebo group, n=51, placebo + 500 mg calcium/d) did not change systolic or
diastolic blood pressure after 9 months’ intervention in individuals with congestive
heart failure. In the Women’s Health Initiative Randomized Trial (Margolis et al.,
2008), postmenopausal women (n= 36 282) were given vitamin D3 (400 IU/d) +
calcium (1000 mg/d) or placebo. After a median of 7-year follow-up, there were
no significant differences between the intervention and placebo groups in systolic
or diastolic blood pressure. A randomized double-blind clinical trial with 1-year
duration (Zittermann et al., 2009), provided vitamin D3 (3320 IU/d - 5 drops of oily
vitamin D) or placebo (5 drops of vitamin D-free oil) to n=200 healthy overweight
individuals with mean 25(OH)D levels of 12ng/mL (n=100 each group). Results
from this study showed no significant time and intervention interaction effects for
systolic or diastolic blood pressure. Jorde et al. (2010) conducted double-blind
clinical randomized clinical trial including 438 overweight or obese participants
using two dosages of vitamin D3 and placebo. One vitamin D3 group received
40,000 IU/week, the second vitamin D3 group received 20,000 IU/week and the
third group received placebo. Additionally, all vitamin D3 groups and placebo
received 500 mg of calcium/d. After 1-year of intervention, findings do not
support the efficacy of vitamin D3 supplementation in reducing blood pressure.
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Inconsistent findings from these clinical trials could be due to: 1) studies were
conducted and/or analyzed using different ranges of vitamin D supplementation
alone or combined with calcium; 2) age range and gender of the participants; 3)
duration of the studies; 4) comorbidities and ethnic background of the
participants and 5) covariates included in the statistical analyses (Pittas et al.,
2010; Witham et al., 2009; Jorde et al., 2010; Beveridge et al., 2015; Larsen et
al., 2012; Witham et al., 2010; Forman et al., 2013; Pfeifer et al., 2001; Sugden
et al., 2008; Margolis et al. 2008). In our study, significant differences in blood
pressure at baseline between vitamin D3 supplementation groups (4,000 IU vs.
6,000 IU/d) could have make the interpretation of findings complex. The 6,000
IU/d vitamin D3 group started with significantly higher levels of systolic and
diastolic blood pressure as compared to the 4,000 IU/d group. On the other hand,
the 4,000 IU/d had a higher percentage of participants on hypertension
medications at baseline. We cannot dismiss that hypertensive medications might
have contributed to the decrease in blood pressure levels in either intervention
group. Nevertheless, throughout the duration of the study any medication change
by the participants were recorded and adjustment for medications were taken
into consideration in the statistical analysis. Those in the 4,000 IU/d group might
benefited less from vitamin D3 supplementation because they had well-treated
blood pressure levels.
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The mechanism on how vitamin D affects blood pressure is poorly
understood. Nonetheless, it has been postulated that vitamin D could affect blood
pressure by regulating through the renin-angiotensin-aldosterone (RAAS) system
(Li et al., 2004; Pilz et al., 2009). Our study did not include RAAS as an outcome
measurement.

Despite the high prevalence of both vitamin D deficiency/insufficiency and
hypertension among our minority population groups, there are no efforts to
establish preventive measures that could benefit individuals by screening for
25(OH)D levels and providing vitamin D3 supplementation. These results ought to
encourage researches to further examine the clinical significance and
implications of vitamin D3 supplementation on elevated blood pressure levels that
could have benefits for individuals with type 2 diabetes. Because evidence is still
inconclusive, our findings support the potential therapeutic role of vitamin D3
supplementation as complementary treatment for blood pressure; however, more
rigorous clinical trials with larger sample sizes are required before recommending
vitamin D3 supplementation exclusively to treat hypertension.
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CHAPTER V: SUMMARY AND CONCLUSIONS
Vitamin D deficiency/insufficiency is still a public health concern particularly
affecting minorities with type 2 diabetes; therefore, more public health awareness
is required to prevent consequences of vitamin D deficiency/insufficiency by
identifying potential risk factors and develop effective interventions. This clinical
trial sought to clarify the effect of vitamin D3 supplementation on kidney function
and cardiovascular disease markers which goes beyond the prevention of bone
health. The study included a sample of Hispanics and African Americans with
type 2 diabetes and hypovitaminosis D who were given two high dosages of
vitamin D3 supplementation (4,000 IU/d and 6,000 IU/d). Although, we found
significant changes in kidney and cardiovascular disease markers,
supplementation with vitamin D3 longer than 6 months may be needed to
determine sustained long term effects in kidney and cardiovascular disease
markers. Vitamin D3 supplements are relatively inexpensive and safe and can be
used as adjunct treatment option to improve kidney function and decrease blood
pressure and consequent cardiovascular disease. Individuals with type 2
diabetes and kidney dysfunction and high blood pressure could benefit from
vitamin D3 supplementation, especially those with low levels of serum 25(OH)D
levels. Clinical recommendations should contain screening and monitoring of
serum 25(OH)D levels: including the measurement of serum 25(OH)D as a
routine assay for high risk populations to provide health care professionals with
the information required to recommend and treat, as well as offering the
appropriate resources as preventive health benefits.
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Our results have set the foundations for further examination of the
mechanisms and metabolic pathways associating vitamin D status with kidney
and cardiovascular disease. Further research could provide more appropriate
means for translation of these findings into recommendations for individuals with
CKD, hypertension and type 2 diabetes. The efficacy of vitamin D3
supplementation as complementary therapy for CKD and blood pressure in
minority and other ethnic groups needs further investigation in larger and longer
duration randomized controlled trials.
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CHAPTER VI: STRENGTHS AND LIMITATIONS
Strengths
Major strengths of the study include: The study included two minority groups
(Hispanics and Blacks) with high prevalence of serum 25(OH)D levels
deficiency/insufficiency and type 2 diabetes. We tested the safety of vitamin D3
supplementation at two high dose levels: 4,000 IU/d and 6,000 IU/d. Throughout
the duration of the study, no adverse effects or signs of toxicity were observed
[IOM tolerable upper limit intake (4,000 IU/d)] for 6 months. These two doses
were safe and effective in increasing participant’s serum 25(OH)D levels in a
population sample who started the study with hypovitaminosis D. We had a low
number of drop-outs [(in the 4,000 IU/d group, n=1) and (in the 6,000 IU/d group,
n=5)] and low non-compliance to the vitamin D3 supplementation [(in the 4,000
IU/d group (n=3), and in the 6,000 IU/d group (n=2)]. We took in consideration
several measurements and confounder variables that could affect the outcomes
such as diet, sun exposure, body mass index (BMI), medications, years with
diabetes where other studies were lacking. Our study recorded any medication
change throughout the duration of the study and adjusted for that in the statistical
analyses. We carefully selected the inclusion criteria to test our outcomes [(i.e.
participants with serum 25(OH)D considered deficient and insufficient, CKD
stages 1-3, etc.]. For the statistical analyses, we used linear mixed models since
we had a longitudinal data with unbalanced number of participants in each study
group (in the 4,000 IU/d group, n=39 and in the 6,000 IU/d group, n=24).
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Limitations
This study had several limitations. The study sample was a convenience
sample and was not randomly selected from the general adult population in
Miami-Dade County; therefore, results of this study cannot be generalized or
extrapolated to the entire U.S. adult population nor Miami-Dade County. Nonrandomized groups could create selection bias because of the non-random
assignment. The advantage of this convenience sample was its large minority
representation; it was recruited from two clinics that have culturally diverse
populations in Miami-Dade County. The relatively small sample size and greater
numbers of female participants were other limitations of the study. Additionally,
not having sufficient number of participants prevented the investigators to
measure differences between ethnic groups (only few Black participants), and
the uneven numbers of participants in each vitamin D3 supplementation group
may have decreased the statistical power of the study. The study lacked a
control group - changes observed in the pre- and post-test might be due not only
to the supplementation with vitamin D3, but to other factors such as change in the
diet, sun exposure, or vitamin D supplements; however, we assessed for
changes in these parameters during the study. We did not assess which
mechanisms underlining vitamin D3 function were acting in kidney disease or
blood pressure and how they were affected or changed by supplementation.
Although trained interviewers who were bilingual in English and Spanish were
present to administer the questionnaires to assess dietary habits of vitamin D,
participants might under- or overestimated their intakes. There was more than
62

50% of participants in each vitamin D3 supplementation group taking
hypertension medications, which possibly influenced blood pressure outcome
over time; however, changes in medications were recorded and medication
usage was used as a control variable in the analysis. Additionally, we advised
participants to keep their medication use constant during the duration of the
study, as prescribed by their primary physician. Lastly, conclusions beyond the 6
months’ supplementation could not be drawn to understand the impact of long
term effects of vitamin D3 supplementation. Studies with longer duration of
supplementation and follow-up maybe needed to see these effects of vitamin D3
supplementation in this sample or other ethnic groups.
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CHAPTER VII: FUTURE RESEARCH
It will be important to comprehend the role and impact of high levels of
vitamin D3 supplementation in larger cohorts with different geographical and
ethnic backgrounds. Additionally, it will be important to examine longitudinal
trajectories of kidney and cardiovascular disease markers, especially in high risk
populations with existing comorbidities. Further evidence will allow for a greater
understanding of the influence of changes in serum 25(OH)D values on kidney
function, cardiovascular disease markers and type 2 diabetes. Investigation of
these mechanisms and metabolic pathways are critical for developing effective
interventions for the translation of findings into recommendations for care among
individuals with type 2 diabetes. As the source for future research, findings from
this study may have public and clinical health implications that could contribute to
the expansion of ethnic-tailored interventions to reduce health disparities and
prevent the high incidence of these chronic diseases in minorities.
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